| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H24N4S |
| Molecular Weight | 292.443 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
S=C(NC1CCCCC1)N2CCC(CC2)C3=CNC=N3
InChI
InChIKey=QKDDJDBFONZGBW-UHFFFAOYSA-N
InChI=1S/C15H24N4S/c20-15(18-13-4-2-1-3-5-13)19-8-6-12(7-9-19)14-10-16-11-17-14/h10-13H,1-9H2,(H,16,17)(H,18,20)
| Molecular Formula | C15H24N4S |
| Molecular Weight | 292.443 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Thioperamide is an antihistamine at H3 and H4 receptors. Thioperamide behaves as both antagonist and inverse agonist.Thioperamide is under preclinical development with Glaxo Wellcome (UK) for the treatment of short-term memory impairment. It has also demonstrated antiarrhythmic effects in preclinical trials. Active development of thioperamide appears to have been discontinued.
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
mouse: thioperamide (10 μg, i.c.v.).
rat: thioperamide (20, 50 μg, i.c.v.).
rat: thioperamide (310 µg/kg, i.v.).
mouse: thioperamide (10 mg/kg, i.p.)
Route of Administration:
Other
